Photodynamic Therapy Using a Protease-Mediated Theranostic Agent Reduces Cathepsin-B Activity in Mouse Atheromata In Vivo | Zendy

Soo-Min Shon | Zendy; Yongdoo Choi | Zendy; Jeong Yeon Kim | Zendy; Dong Kun Lee | Zendy; JinYong Park | Zendy; Dawid Schellingerhout | Zendy; DongEog Kim | Zendy

Open Access

Photodynamic Therapy Using a Protease-Mediated Theranostic Agent Reduces Cathepsin-B Activity in Mouse Atheromata In Vivo

Author(s) -

Soo-Min Shon,

Yongdoo Choi,

Jeong Yeon Kim,

Dong Kun Lee,

JinYong Park,

Dawid Schellingerhout,

DongEog Kim

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301290

Subject(s) - in vivo , cathepsin b , photodynamic therapy , protease , cathepsin , cancer research , medicine , biology , immunology , pathology , chemistry , enzyme , biochemistry , microbiology and biotechnology , organic chemistry

To investigate whether an intravenously injected cathepsin-B activatable theranostic agent (L-SR15) would be cleaved in and release a fluorescent agent (chlorin-e6) in mouse atheromata, allowing both the diagnostic visualization and therapeutic application of these fluorophores as photosensitizers during photodynamic therapy to attenuate plaque-destabilizing cathepsin-B activity by selectively eliminating macrophages.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research